Literature DB >> 31841737

Dysbiosis of gut microbiota in patients with neuromyelitis optica spectrum disorders: A cross sectional study.

Ziyan Shi1, Yuhan Qiu1, Jiancheng Wang1, Yihuan Fang2, Ying Zhang1, Hongxi Chen1, Qin Du1, Zhengyang Zhao1, Chao Yan1, Mu Yang3, Hongyu Zhou4.   

Abstract

BACKGROUND: Accumulating evidence points to an association of alternations in the gut microbiota with health and disease, including the development of neurological diseases. However, there are relatively scarce studies of the role of the gut microbiota in neuromyelitis optica spectrum disorders (NMOSD). Therefore, the aim of the present study was to evaluate the differences in the intestinal microbiota composition between patients with NMOSD and healthy control subjects.
METHODS: This was a cross-sectional study. Stool samples were obtained from 20 patients with NMOSD and 20 healthy family members of the patients as controls (HC). The bacterial 16S rRNA gene amplification sequencing (V3-V4 region) was used to detect the composition and structure of the intestinal microbiota community in the two groups.
RESULTS: The gut microbiota compositions clearly differed between the NMOSD and HC groups, although there was no significant difference in the overall microbial community structure. In detail, patients with NMOSD had an increased abundance of the pathogenic genera Flavonifractor (P = .004) and Streptococcus (P = .007) compared with the HC. In addition, several intestinal commensal bacteria were detected at significantly lower abundance in the NMOSD patients compared to the controls, including Faecalibacterium, Lachnospiracea_incertae_sedis, Prevotella, Blautia, Roseburia, Romboutsia, Coprococcus, and Fusicatenibacter (all P < .05). ROC curve analysis suggested that gut microbiota genera had potential to distinguish NMOSD from controls. Functional analysis further indicated that the gut microbiome of NMOSD patients was associated with three significantly downregulated metabolic pathways: "Photosynthesis" (P < .001), "Photosynthesis proteins" (P < .001), and "Thiamine metabolism" (P = .007). These differences remained significant even after correction for multiple comparisons (all PFDR < 0.05).
CONCLUSION: Our results reveal the dysbiosis of intestinal bacteria and regarding metabolic abnormalities in patients with NMOSD. Further studies are warranted to elucidate the potential mechanism by which dysbiosis of microbiota contributes to the onset and progression of NMOSD.
Copyright © 2019. Published by Elsevier B.V.

Entities:  

Year:  2019        PMID: 31841737     DOI: 10.1016/j.jneuroim.2019.577126

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  7 in total

Review 1.  Gastrointestinal Dysfunction in Parkinson's Disease.

Authors:  Delaram Safarpour; Kaveh Sharzehi; Ronald F Pfeiffer
Journal:  Drugs       Date:  2022-01-25       Impact factor: 9.546

2.  The profile of gut microbiota and central carbon-related metabolites in primary angle-closure glaucoma patients.

Authors:  Haijun Gong; Rui Zeng; Qiguan Li; Yao Liu; Chengguo Zuo; Jiawei Ren; Ling Zhao; Mingkai Lin
Journal:  Int Ophthalmol       Date:  2022-02-11       Impact factor: 2.031

3.  Effects of fenugreek seed extracts on growth performance and intestinal health of broilers.

Authors:  Ling Yang; Liang Chen; Ke Zheng; Yu-Jing Ma; Rong-Xiang He; Muhammed Adebayo Arowolo; Ying-Jun Zhou; Ding-Fu Xiao; Jian-Hua He
Journal:  Poult Sci       Date:  2022-04-30       Impact factor: 4.014

Review 4.  Can Gut Microbiota Affect Dry Eye Syndrome?

Authors:  Jayoon Moon; Chang Ho Yoon; Se Hyun Choi; Mee Kum Kim
Journal:  Int J Mol Sci       Date:  2020-11-10       Impact factor: 5.923

5.  Clinical Features and Gut Microbial Alterations in Anti-leucine-rich Glioma-Inactivated 1 Encephalitis-A Pilot Study.

Authors:  Xueying Ma; Lili Ma; Zhanhang Wang; Yingying Liu; Ling Long; Xiaomeng Ma; Hao Chen; Zhaoyu Chen; Xiuli Lin; Lei Si; Xiaohong Chen
Journal:  Front Neurol       Date:  2020-10-27       Impact factor: 4.003

6.  Tryptamine Attenuates Experimental Multiple Sclerosis Through Activation of Aryl Hydrocarbon Receptor.

Authors:  Nicholas Dopkins; William Becker; Kathryn Miranda; Mike Walla; Prakash Nagarkatti; Mitzi Nagarkatti
Journal:  Front Pharmacol       Date:  2021-01-25       Impact factor: 5.810

7.  Meta-analysis of the Parkinson's disease gut microbiome suggests alterations linked to intestinal inflammation.

Authors:  Stefano Romano; George M Savva; Janis R Bedarf; Ian G Charles; Falk Hildebrand; Arjan Narbad
Journal:  NPJ Parkinsons Dis       Date:  2021-03-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.